Custom studies for companies planning Risk Evaluation and Mitigation Strategies research under FDA Title IX regulations.
Beginning as early as Phase II we work with your commercialization team to identify critical safety and communications issues that your future REMS program must address and resolve.
As your new product moves towards market, we work with your team to develop and test your Medication Guide, Patient Package Insert and other ETASU materials to ensure that they are clear, concise and accessible to Physicians, Pharmacists, Patients and other stakeholders targeted by your REMS Communications Plan.
This pre-launch research is conducted through a series of focus groups followed by qualitative in-depth interviews with each target audience.
Once your new product has been introduced, we work with your Pharmaco-vigilance team to track awareness, familiarity, use and understanding of REMS materials among your various audiences at 18, 36 and 84 months post-launch as mandated by the FDA.
This REMS tracking is conducted through a series of Internet or phone-based surveys.
We also offer follow-up qualitative research to examine in greater depth and detail areas where communications goals have not been met and REMS safety and administration materials have been found wanting.